Efficacy and Safety of Topical Anticholinergics in the Treatment of Primary Axillary Hyperhidrosis: A Systematic Review and Meta-analysis
- 문서 유형
- 연구출판물 · 리뷰논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- CLINICAL DRUG INVESTIGATION46(6) · pp.583 · 2026
- 피인용
- Web of Science 0Scopus 0
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2024 2.7
- ISSN
- 1173-2563
저자
- Kim, Jiah제1저자Kyungsung Univ, Coll Pharm, 309 Suyeong Ro, Busan 48434, South Korea
- Han, NayoungJeju Natl Univ, Coll Pharm, 102 Jejudaehak Ro, Jeju 63241, South Korea
- Koo, HyunjiKyungsung Univ, Coll Pharm, 309 Suyeong Ro, Busan 48434, South Korea
- Kim, YounghwaKyungsung Univ, Dept Food Sci & Biotechnol, BB21plus Project Team, 309 Suyeong Ro, Busan 48434, South Korea
- 황은정Pusan Natl Univ Yangsan Hosp, Dept Pharm, 20 Geumo Ro, Yangsan Si 50612, Gyeongsangnam d, South Korea
- 김민수Pusan Natl Univ, Coll Pharm, 63 Busandaehak Ro, Busan 46241, South Korea
- Staatz, Christine E.Univ Queensland, Pharm Australia Ctr Excellence, Sch Pharm & Pharmaceut Sci, Brisbane, Australia
- Baek, In-hwan교신저자Kyungsung Univ, Coll Pharm, 309 Suyeong Ro, Busan 48434, South Korea
초록
BackgroundTopical anticholinergic agents are non-invasive treatment options for primary axillary hyperhidrosis (PAH). Sofpironium bromide was recently approved by the US Food and Drug Administration (FDA). A comprehensive evaluation of the efficacy and safety of available topical anticholinergics may inform clinical practice.ObjectivesTo assess the efficacy and safety of topical anticholinergic therapies for PAH through systematic review and meta-analysis of randomized controlled trials (RCTs).MethodsFive databases were searched on September 9, 2024. Primary outcomes included a >= 2-point improvement in the Hyperhidrosis Disease Severity Scale (HDSS) and >= 50% reduction in gravimetric sweat production (GSP). Secondary outcomes included subjective symptom improvement and objective sweat reduction. Safety outcomes included treatment-emergent adverse events (TEAEs), anticholinergic-related adverse events, and local application site reactions. The review protocol was registered in PROSPERO (CRD42024583376).ResultsEight RCTs (n = 1921) that evaluated glycopyrronium, sofpironium bromide, and umeclidinium were included. Topical agents significantly outperformed placebos for HDSS >= 2-point improvement (risk ratio [RR]: 2.40; 95% confidence interval [CI]: 2.01-2.86) and GSP >= 50% reduction (RR: 1.43; 95% CI: 1.21-1.70). Sofpironium was the most effective HDSS treatment, whereas glycopyrronium showed highest efficacy against GSP. Topical agents were associated with increased risk of TEAEs (RR: 1.43; 95% CI: 1.14-1.79), with sofpironium associated with highest risk of dry mouth and glycopyrronium with highest risks for mydriasis and constipation.ConclusionsTopical anticholinergic agents are effective for PAH treatment, with distinct efficacy and safety profiles. Although the available evidence is limited by the small number of trials, short follow-up durations, and heterogeneity in outcome reporting, these findings support the role of topical anticholinergic therapy as an effective non-invasive option for PAH.
키워드
식별자
- Scopus EID
- 2-s2.0-105035814914
- WoS UID
- 001741925100001



로그인
연구물 목록으로